FOLR1 and cancer: Due to its differential expression and the ability of FRα to internalize large molecules, FRα is well suited for antibody-drug conjugate (ADC)- based therapeutic strategies that can couple the targeting and pharmacokinetic features of an antibody with the cancer-killing impact of a cytotoxic agent (65).